Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
118.3(c) 118(c) 116.65(c) 115.85(c) 115.1 Last
128 802 130 214 86 400 110 168 36 637 Volume
+1.37% -0.25% -1.14% -0.69% -0.65% Change
More quotes
Financials
Sales 2020 306 M 347 M 347 M
Net income 2020 21,3 M 24,1 M 24,1 M
Net cash position 2020 822 M 931 M 931 M
P/E ratio 2020 239x
Yield 2020 -
Sales 2021 254 M 288 M 288 M
Net income 2021 -68,3 M -77,4 M -77,4 M
Net cash position 2021 651 M 738 M 738 M
P/E ratio 2021 -47,4x
Yield 2021 -
Capitalization 3 786 M 4 283 M 4 287 M
EV / Sales 2020 9,68x
EV / Sales 2021 12,3x
Nbr of Employees 516
Free-Float 94,9%
More Financials
Company
MorphoSys AG is one of the world's leading groups of biotechnology. Net sales break down by activity as follows: - development of antibody for therapeutic applications in partnership with pharmaceutical and biotechnology companies (52.2%): for treating rheumatoid arthritis, cancers and infectious diseases; - proprietary development of therapeutic antibodies and peptides (47.8%). At the end of 2019, the MorphoSys... 
Sector
Biotechnology & Medical Research
Calendar
08/05 | 04:00pmEarnings Release
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
07/07MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
07/02MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/26MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/24MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/22MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/18MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/15Coronavirus vaccine maker CureVac plans U.S. listing in July
RE
06/15Coronavirus vaccine maker CureVac plans U.S. listing in July
RE
06/15Coronavirus vaccine maker CureVac plans U.S. listing in July
RE
06/15MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/10MORPHOSYS : Goldman Sachs reiterates its Neutral rating
MD
06/09MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/04MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/02MORPHOSYS : to Present at Upcoming Virtual Investor Conferences
PU
06/02MORPHOSYS : to Present at Upcoming Virtual Investor Conferences
EQ
More news
News in other languages on MORPHOSYS AG
07/07MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
07/07MORPHOSYS AG : Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europawe..
07/02MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
07/02MORPHOSYS AG : Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europawe..
06/26MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
More news
Analyst Recommendations on MORPHOSYS AG
More recommendations
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 125,49 €
Last Close Price 115,85 €
Spread / Highest target 38,1%
Spread / Average Target 8,32%
Spread / Lowest Target -65,6%
EPS Revisions
Managers
NameTitle
Jean-Paul Kress CEO & Member-Supervisory Board
Marc Cluzel Chairman-Supervisory Board
Roland Wandeler Chief Operating Officer
Jens Holstein Chief Financial Officer
Malte Peters Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-8.64%4 283
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344